Exhibit 990

Memorandum on Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

Exhibit 990 · Presidential memorandum

Memorandum on Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

Over time, however, the FDA's requirements have permitted drug companies to include less information, particularly in broadcast advertising, and drug manufacturer advertising has skyrocketed in recent decades.

Directs the HHS Secretary to act to increase risk information required in DTC advertisements to the extent permitted by law and the FDA Commissioner to enforce the advertising provisions of the FDCA. The Daily Compilation notes an original was not available for verification.

Source: The White House (President Donald J. Trump)
Date: 9 September 2025
Quoted from: Para. 2
Grade: Primary record
Document: https://www.govinfo.gov/content/pkg/DCPD-202500906/html/DCPD-202500906.htm
Accessed: 2026-11-10
Cited by: Findings citing this exhibit

Cited by

Finding INF-1.9: Primary record On 9 September 2025 the President directed HHS and FDA to act on direct-to-consumer drug advertising, and FDA announced thousands of warning letters, about 100 cease-and-desist letters and rulemaking to remove the "adequate provision" option. FDA's announcement states that warning letters to pharmaceutical companies fell to one in 2023 and zero in 2024.